In a new study, researchers from the Indian Council for Medical Research – National Institute of Virology have found that Covaxin is effective against the Brazilian version, B.1.128.2.
This finding is close to the heels of their study, which also suggests that Covaxin is effective against the UK variant as well as the Indian variant (double mutant) B.1.617.
India currently uses two Covid-19 vaccines – Covaxin from Bharat Biotech and Covishield from the Serum Institute in India – to vaccinate people across the country.
In this new study, published in the preprint bioRxiv on April 30, the researchers showed that Covaxin was effective against the Brazilian version. The study showed that the two-dose regimen significantly increased the titer of IgG antibodies and neutralized the efficacy compared to the Brazilian variant and variant D61
Led by NIV scientists Gajanan Sapkal, Pragya Yadav, Priya Abraham and others, they said this was a strong neutralization of variants B1 and B.126.96.36.199 among vaccine recipients.
The researchers determined the IgG immune response and neutralizing activity of 19 specimens of reconstituted sera obtained from reconstituted cases of Covid-19 and confirmed for Great Britain (B.1.1.7), South Africa (B.1.351) and Brazil (B.188.8.131.52 ) variants (15 to 113 days after a positive test) and from 42 participants immunized with inactivated Covid-19 vaccine, BBV 152 (Covaxin), as part of a phase II clinical trial (two months after the second dose).
The response was observed in recovered cases, but the study found a better response than samples from Covaxin beneficiaries, the researchers said.
India has reported cases of SARS-CoV-2 UK variant (B.1.1.7). Recently, the South African variant (B.1.351) and the Brazilian variant P2 line (B.184.108.40.206) have also been found in international tourists.
The impact on the emergence of these new variants on the efficacy of currently available Covid-19 vaccines or the neutralizing ability of sera of individuals naturally infected with earlier circulating strains is currently being investigated.
Although some vaccines appear to be effective against the UK option, efficacy against the South African version has been shown to be lower.
According to a recent report by the National Center for Disease Control (NCDC), among 15,000 sequenced samples, 11 percent include these anxiety options.
By the first week of April, the number of cases with options in the UK, South Africa and Brazil had reached 948.